ATAI is looking into different ways to increase the human healthspan and reverse aging

Technological advances in areas like genomics, stem cell therapy, immunology and nanotechnology will change how we age.

We believe that

• the future of medicine will become increasingly personalized
• we should ‘predict and prevent’ disease, or at least detect it earlier
• we have to eliminate cellular senescence, the state in which cells no longer divide
• we must explore the process of autophagy to help cure neurodegenerative diseases
• we have to leverage the potential of neurotechnology and cognitive enhancement

Christian Angermayer

Founder

Strategy and investor relations

• Serial entrepreneur and investor
• Co-founder, Ribopharma (RNAi translation, today Alnylam, $10bn market cap)
• Raised $1.5bn+ raised over the last 20 years for portfolio companies
• Invests across the entire lifecycle of a company and has been involved in more than 40 successful IPO and M&A transactions

Lars Wilde

Co-founder

Drug discovery and compound sourcing

• COO and Co-founder, COMPASS Pathways
• Former Co-founder and MD, Springlane
• Prior experience with Waterland Private Equity; VivaNeo, a global IVF clinics group; Boston Consulting Group
• Background in finance and management

Florian Brand

Co-founder and CEO

Drug development and operations

• Interim CEO, Perception Neuroscience
• Former Co-founder and MD, Springlane
• Prior experience with Rocket Internet; Allianz; Tanzanian-German health program
• Background in economics and management

Simon Seibold

Associate

Investments and business development

• Founder of AI-based application with neural network approach
• Experience in venture capital with focus on digital health and therapeutics
• Background in psychology, medicine and management

Philipp Schreiber

Associate

Drug discovery and compound sourcing

• Portfolio development at Apeiron Investment Group
• Experience in M&A transactions, venture capital and strategic management
• Background in management, entrepreneurship and business law

ATAI is supporting the revival of psychedelic compounds, such as psilocybin and ketamine, in the treatment of mental health conditions

Depression, anxiety, post-traumatic stress disorder, obsessive-compulsive disorder, bipolar disorder and other psychiatric conditions are increasingly becoming a burden for patients, families and societies.

We believe that

• using psychedelic compounds in therapy could provide an opportunity to significantly advance psychiatry
• treatment solutions should be as convenient, cost-effective and fast as possible
• clinical evidence has to meet the highest scientific standards
• fully integrated mental health solutions are the future

ATAI is leveraging the potential of artificial intelligence (AI) and big data analytics to optimize and accelerate the drug development process

Technological innovation will enable us to consolidate and make sense of vast amounts of previously inaccessible data.

We believe that

• technology can be used to accelerate the identification and incubation of drug candidates and compounds
• AI and big data will improve clinical trial design, comparison and decision-making
• AI has a leading role in developing personalized therapeutics
• predictive analytics through unified machine learning models help us to predict the toxicity of drugs and the efficacy of combination therapeutics

Sorry,

there are no positions available at this time.

Please check back soon.